Clinical players and healthcare payers: aligning perspectives on the cost-effectiveness of next-generation sequencing in oncology

Brett Doble; Paula Lorgelly

doi:10.2217/pme.14.81

Clinical players and healthcare payers: aligning perspectives on the cost-effectiveness of next-generation sequencing in oncology

Per Med. 2015 Jan;12(1):9-12. doi: 10.2217/pme.14.81.

Authors

Brett Doble¹, Paula Lorgelly¹

Affiliation

¹ Centre for Health Economics, Monash Business School, Monash University, Clayton, Victoria, Australia.

PMID: 29767540
DOI: 10.2217/pme.14.81

No abstract available

Keywords: cancer; clinical tumor sequencing; cost–effectiveness analysis; economic evaluation; reimbursement; value assessment; whole-genome sequencing.